DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

today announced it has exercised early the option to license from GenFleet Therapeutics VS-7375 (also known as GFH375), a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor.

after one prior systemic therapy – the same indication given to Amgen's Lumakras (sotorasib) when it became the first KRAS inhibitor to be approved in the US in May 2021. While the wording on ...

They will also work on an inhibitor of KRAS G12C that could compete with sotorasib (BI 1823911) and an MEK inhibitor (BI 3011441), as well as a novel undisclosed bi-specific TRAILR2 agonist.

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Target validation is the process by which the predicted molecular target – for example protein or nucleic acid – of a small molecule is verified. Target validation can include: determining the ...

Ozempic (semaglutide) Glucagon-like peptide-1 receptor agonist To reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, and cardiovascular death in ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Medical experts discuss approaches to patient education on managing potential adverse events associated with adagrasib and other KRAS-targeted therapies.

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...